TXG (10x) Expected net earnings per share growth this year
10x Genomics, Inc. (TXG) unites leading geneticists through complex R&D challenges, retaining staff with generous RSUs. The company is currently optimizing its model by increasing profits from reagent sales. The proportional EPS growth compared to last year, standing at -78.90, reflects the current state of profit dynamics. Single-cell analysis technologies make the issuer's platforms the gold standard in oncology therapy and fundamental genetics.
Financial and market metric breakdowns for 10x Genomics Inc (TXG)
- price and consensus price forecast:
- business market valuation indicators:
- shareholders' equity book value data:
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio 10x Genomics, Inc.|TXG - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient 10x Genomics Inc|TXG - Company Debts|Debt to Book Value Ratio 10x Genomics|TXG - Company Long-Term Debts|Company Current Liabilities 10x Genomics|Interim Coverage Ratio 10xgenomics.com
- net income and valuation ratios data:
TXG - Net Income|Future Net Profit 10x Genomics, Inc.|TXG - Price to Earnings Ratio|Price to Future Earnings Ratio 10x Genomics, Inc.|TXG - PEG Multiple|Enterprise Value to EBITDA Multiple 10x Genomics|TXG - Operating profit EBITDA|Earnings per share for the last 12 months 10x Genomics|TXG - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months 10xgenomics.com|TXG - Earnings growth in current year|Earnings growth forecast for next year 10x Genomics, Inc.
- revenue and sales proceeds data:
Basic company analysis:10x Genomics Corp
This indicator measures the annual growth of net income per share, allowing for a real-time assessment of business scaling rates between quarterly reports. By analyzing the percentage increase in annual net income per share, an investor can see how the monetization of revolutionary single-cell analysis systems and recurring reagent sales convert into actual financial results for 10x Genomics, Inc. (TXG).
Direct competitors
Tempus AI, Inc (TEM) - Earnings growth in current year|Earnings per share growth in current year Qiagen|IONS: Earnings per share increase in current year|Net earnings per share growth this year RGEN (Repligen)|Expected net earnings per share growth this year Avidity Biosciences Inc|Earnings growth in current year CRSP (crisprtx.com)|WGS: Earnings per share growth this year|RARE: Net earnings per share growth this year|Earnings per share trend in current year BEAM|Sarepta (SRPT) - Earnings per share growth in current year|TWST - Expected net earnings per share growth this year|Earnings per share growth in current year Intellia|Earnings per share growth rate in current year Stoke Therapeutics STOK|Earnings growth in current year BLFS|Wave Life Sciences - Earnings per share growth this year|Earnings growth in current year MAZE (Maze Therapeutics, Inc.)|Earnings growth in current year Sionna Pharma SION|Prime Medicine Bio - Earnings growth in current year|Earnings per share increase in current year TSHA (Taysha)|QURE: Earnings growth in current year|MGTX - Expected net earnings per share growth this year|Net earnings per share growth this year RGNX|SLDB: Earnings per share increase in current year|Earnings per share growth in current year ocugen.com (OCGN)|Expected net earnings per share growth this year PacBio Corp|Earnings per share growth in current year Benitec Biopharma BNTC|DSGN: Earnings per share growth this year|RCKT - Earnings per share growth in current year|4dmoleculartherapeutics.com (FDMT) - Net earnings per share growth this year|lexeotx.com (LXEO) - Earnings per share growth in current year|Korro Bio, Inc (KRRO) - Earnings growth in current year|EDIT (editasmedicine.com) - Earnings growth in current year|Earnings per share growth this year SLN (silence-therapeutics.com)|Earnings per share growth in current year proqr.com (PRQR)|Codexis - Earnings per share growth this year|Earnings growth in current year SGMO (Sangamo Therapeutics)|Earnings growth in current year nautilus.bio NAUT|Metagenomi Inc. - Earnings growth in current year|DTIL (Precision BioSciences Inc.) - Earnings per share growth this year|GBIO: Earnings growth in current year|Earnings per share growth rate in current year Boundless Bio, Inc (BOLD)|XCUR (Exicure) - Earnings growth in current year|Net earnings per share growth this year Imunon (IMNN)|Earnings growth in current year PHIO|Mustang Bio - Earnings per share growth this year|TransCode Therapeutics, Inc. - Net earnings per share growth this year|Expected net earnings per share growth this year Bionano Genomics, Inc. (BNGO)|APDN - Earnings per share growth in current year|Earnings per share increase in current year BLUE (Bluebird Bio)|ImmunoPrecise (IPA) - Earnings per share growth in current year|OMGA: Net earnings per one share growth for the current year|Earnings per share growth in current year Singular Genomics Systems, Inc.|Earnings growth in current year Regulus Therapeutics, Inc.|Net earnings per share growth this year SYRS (Syros)|TBIO - Earnings per share growth rate in current year|Earnings per share growth in current year TRACON Pharmaceuticals, Inc. TCON|Unity Biotechnology (UBX) - Earnings per share growth rate in current year
